Biocorp Production

Biocorp Production ROE

Delisted

The Return on Equity (ROE) of Biocorp Production (ALCOR.PA) as of Oct 26, 2026 is -26.47 %. In the previous year, Return on Equity (ROE) was 9.42 % — a change of -380.88% (lower).

ROE

-26.47 %

YoY

-380.88%

Last updated:

In 2022, Biocorp Production's return on equity (ROE) was -26.47 %, a -380.88% increase from the 9.42 % ROE in the previous year.

The Biocorp Production ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2015
-12.05 EUR
Jan 1, 2016
-71.22 EUR
Jan 1, 2017
593.96 EUR
Jan 1, 2018
291.50 EUR
Jan 1, 2019
3,010.42 EUR
Jan 1, 2020
-43.76 EUR
Jan 1, 2021
9.42 EUR
Jan 1, 2022
-26.47 EUR
The Biocorp Production ROE history
YEARROEYoY
-26.47 %-380.88%
9.42 %-121.53%
-43.76 %-101.45%
3,010.42 %+932.73%
291.50 %-50.92%
593.96 %-933.95%
-71.22 %+491.02%
-12.05 %-1,648.32%
0.78 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biocorp Production Stock analysis

What does Biocorp Production do? Biocorp Production SA is a French company in the medical technology industry that manufactures innovative solutions for drug administration and injections. It was founded in 2004 under the name Biocorp sur mesure by Eric Dessertenne and later transformed into Biocorp Production SA. The business model of Biocorp Production SA is to produce innovative medical devices that can be used in medical applications. The company specializes in the development of smart devices that support injection administration. The devices produced by Biocorp can be operated by medical professionals or by patients themselves. One of the core areas of Biocorp Production SA is the development of smart medical technologies that aid in medication management. One such product is Vyoo, a device that assists patients in injecting medications. It is a digital device that facilitates injection administration and makes dosing safer. In addition to developing smart devices, Biocorp also offers other services, such as in the field of clinical trials for medical applications. The company works closely with pharmaceutical companies to develop medical devices and solutions for drug administration. Another important product is Mallya, an intelligent insulin administration system specifically designed for diabetes patients. It enables automated insulin administration tailored to the patient's needs, thereby improving their quality of life. Furthermore, Biocorp Production SA is also involved in the field of wearable medical technology. One example of a wearable device is Easylog, an electronic device for monitoring medical conditions. This device is particularly useful for patients with chronic diseases such as diabetes or asthma. Over the years, Biocorp Production SA has received numerous awards for its innovative products and services. For example, the company received the Innovation Award at the "Innovation Awards" in Paris in 2017 for the Mallya device. Overall, the company currently employs over 60 employees and has its headquarters in Issoire. It has branches in Germany and the USA. The products of Biocorp Production SA are sold in more than 80 countries worldwide. In summary, Biocorp Production SA is a leading provider of smart medical devices for drug administration and injections. The company strives to develop innovative solutions for the medical industry that are tailored to the needs of patients and medical professionals. With the products of Biocorp Production SA, medication administration becomes safer, easier, and more accurate. Biocorp Production is one of the most popular companies on Eulerpool.

ROE Details

Decoding Biocorp Production's Return on Equity (ROE)

Biocorp Production's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Biocorp Production's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Biocorp Production's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Biocorp Production’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Biocorp Production stock

Return on Equity (ROE) of Biocorp Production is -26.47 % in 2022.

Return on Equity (ROE) of Biocorp Production changed from 9.42 % to -26.47 %, representing a -380.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Biocorp Production since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Biocorp Production with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Biocorp Production

All Key Metrics — Biocorp Production